These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25263302)

  • 21. Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.
    Esteban R; Buti M
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):445-53. PubMed ID: 23199503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P; Reddy KR
    Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatments for chronic hepatitis C virus infection.
    Corouge M; Pol S
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
    Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
    J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.
    Ghany MG; Nelson DR; Strader DB; Thomas DL; Seeff LB;
    Hepatology; 2011 Oct; 54(4):1433-44. PubMed ID: 21898493
    [No Abstract]   [Full Text] [Related]  

  • 26. [Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].
    Zuckerman E; Safadi R; Oren R; Shibolet O; Baruch Y; Bruck R; Lurei Y; Kaspa RT; Abu-Mouch S; Shouval D; Ben-Ari Z;
    Harefuah; 2012 Dec; 151(12):709-14, 719. PubMed ID: 23330266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

  • 28. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients.
    Soriano V; Sherman KE; Rockstroh J; Dieterich D; Back D; Sulkowski M; Peters M
    AIDS; 2011 Nov; 25(18):2197-208. PubMed ID: 21866039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future treatment of patients with HCV cirrhosis.
    Bourlière M; Khaloun A; Wartelle-Bladou C; Oules V; Portal I; Benali S; Adhoute X; Castellani P
    Liver Int; 2012 Feb; 32 Suppl 1():113-9. PubMed ID: 22212581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Letter: Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis.
    Wiegand J; Maasoumy B; Buggisch P; Buslau A; Schiefke I; Berg T; Wedemeyer H; Sarrazin C; Hinrichsen H
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1342-4. PubMed ID: 24803258
    [No Abstract]   [Full Text] [Related]  

  • 34. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.
    Cento V; Di Paolo D; Di Carlo D; Micheli V; Tontodonati M; De Leonardis F; Aragri M; Antonucci FP; Di Maio VC; Mancon A; Lenci I; Manunta A; Taliani G; Di Biagio A; Nicolini LA; Nosotti L; Sarrecchia C; Siciliano M; Landonio S; Pellicelli A; Gasbarrini A; Vecchiet J; Magni CF; Babudieri S; Mura MS; Andreoni M; Parruti G; Rizzardini G; Angelico M; Perno CF; Ceccherini-Silberstein F
    Dig Liver Dis; 2015 Feb; 47(2):157-63. PubMed ID: 25544656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Bailly F; Virlogeux V; Dufour C; Pradat P; Hézode C; Larrey D; Alric L; Samuel D; Bourlière M; Métivier S; Zarski JP; Fontaine H; Loustaud-Ratti V; Serfaty L; Bronowicki JP; Carrat F; Zoulim F;
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 37. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
    Marks KM; Jacobson IM
    Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

  • 39. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives.
    Welsch C; Jesudian A; Zeuzem S; Jacobson I
    Gut; 2012 May; 61 Suppl 1():i36-46. PubMed ID: 22504918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M
    Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.